Related Experiment Video

Updated: Aug 19, 2026

Hemodynamic Precision in the Neonatal Intensive Care Unit using Targeted Neonatal Echocardiography
09:31

Hemodynamic Precision in the Neonatal Intensive Care Unit using Targeted Neonatal Echocardiography

Published on: January 27, 2023

Ibuprofen in the management of neonatal Patent Ductus Arteriosus

Simon Keady1, Anthony Grosso

  • 1Women and Children's Services, University College London Hospitals NHS Foundation Trust, UK. simon.keady@uclh.nhs.uk

Intensive & Critical Care Nursing
|February 1, 2005
PubMed

Insights

Patent Ductus Arteriosus (PDA) affects 25% of preterm neonates. Intravenous Ibuprofen is a new UK-licensed treatment option, reviewed for efficacy, side effects, and administration in managing this critical condition.

Area of Science:

  • Neonatal medicine
  • Pediatric cardiology
  • Pharmacology

Background:

  • Patent Ductus Arteriosus (PDA) affects approximately 25% of neonates born before 33 weeks gestation.
  • Untreated PDA increases mortality risk in preterm infants.

Purpose of the Study:

  • To review the clinical efficacy of intravenous Ibuprofen for PDA treatment.
  • To examine the side effect profile, dosing, and administration of this new formulation.
  • To discuss current warnings and precautions associated with intravenous Ibuprofen for PDA.

Main Methods:

  • Literature review of clinical efficacy.
  • Analysis of side effect profile and dosing information.
  • Examination of safety warnings and precautions.

Main Results:

  • Intravenous Ibuprofen is a newly licensed treatment for PDA in the UK.
  • The review covers clinical efficacy, side effects, and administration guidelines.
  • Important warnings and precautions are discussed.

Conclusions:

  • Intravenous Ibuprofen offers a new therapeutic option for neonatologists managing PDA.
  • This review provides essential information for the safe and effective use of this medication.
  • Understanding the efficacy and safety profile is crucial for optimal patient outcomes.

More Related Videos

Methods for In Vivo Biomechanical Testing on Brachial Plexus in Neonatal Piglets06:51

Methods for In Vivo Biomechanical Testing on Brachial Plexus in Neonatal Piglets

Published on: December 19, 2019

Related Concept Videos

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
Mitral Stenosis III: Medical Management01:26

Mitral Stenosis III: Medical Management

Mitral stenosis, a condition marked by the narrowing of the mitral valve, necessitates an integrated approach for effective management. This approach includes preventative measures, medical therapy, and surgical interventions to reduce symptoms and prevent complications.PreventionPrevention of mitral stenosis primarily focuses on reducing the incidence of bacterial infections, particularly streptococcal infections, which can lead to rheumatic fever and subsequent valvular damage. Timely...
Mitral Regurgitation III: Medical Management01:25

Mitral Regurgitation III: Medical Management

Mitral regurgitation (MR) is characterized by retrograde blood circulation from the left ventricle into the left atrium due to inadequate mitral valve closure. The severity of the condition, symptoms, and underlying cause determine treatment strategies.Monitoring and Pharmacological TreatmentPatients with mild to moderate MR typically do not need immediate intervention but regular monitoring to assess progression and guide treatment. Patients with mild MR should have an echocardiogram every 3-5...
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Mitral Regurgitation IV: Nursing Management01:28

Mitral Regurgitation IV: Nursing Management

Mitral regurgitation (MR) is a condition where the mitral valve does not close properly, leading to the backward flow of blood from the left ventricle into the left atrium during systole. This condition can arise from various causes, including rheumatic fever, infective endocarditis, or degenerative valve disease. Effective nursing management is crucial to optimizing patient outcomes and involves comprehensive assessment and targeted interventions.Comprehensive Patient AssessmentA detailed...